Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | _UBC13, UbcH-ben, UbcH13 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ubiquitin-conjugating enzyme E2, putative | _UBC13, UbcH-ben, UbcH13 | 152 aa | 153 aa | 32.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.4858 | 0.5 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.4858 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.4858 | 0.4858 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | Ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.4858 | 0.4858 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.4858 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Leishmania major | ubiquitin-conjugating enzyme e2, putative | 0.0046 | 0.4858 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trypanosoma brucei | ubiquitin-protein ligase, putative | 0.0046 | 0.4858 | 1 |
Plasmodium vivax | ubiquitin-conjugating enzyme E2 N, putative | 0.0046 | 0.4858 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0029 | 0.1906 | 0.1906 |
Plasmodium falciparum | ubiquitin-conjugating enzyme E2 N, putative | 0.0046 | 0.4858 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.4858 | 0.4858 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0029 | 0.1906 | 0.1906 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme E2, putative | 0.0046 | 0.4858 | 0.5 |
Toxoplasma gondii | ubiquitin-conjugating enzyme subfamily protein | 0.0046 | 0.4858 | 0.5 |
Loa Loa (eye worm) | ubiquitin conjugating enzyme protein 13 | 0.0046 | 0.4858 | 0.4858 |
Entamoeba histolytica | ubiquitin-conjugating enzyme family protein | 0.0046 | 0.4858 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0017 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 11.337 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS for the identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay reconfirm. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485273, AID485343, AID493155] | ChEMBL. | No reference |
IC50 (functional) | = 17.146 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS for the identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485273, AID485343, AID493182] | ChEMBL. | No reference |
IC50 (functional) | > 20 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of UBC13 Polyubiquitin Inhibitors using a Bfl-1 counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485273, AID485343] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 70.7946 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.